# NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Study · id `cardio:ct-nct02817360` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02817360](<https://clinicaltrials.gov/study/NCT02817360>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02817360

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2400 participants.

## Technical summary

Registry record NCT02817360. Randomized; no masking; primary purpose treatment. Start 2016-02 (registry gives no type); primary completion 2025-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2400 participants (planned count; ClinicalTrials.gov record NCT02817360, source copy `cardio:ctgov-nct02817360-2023-03-14`, retrieved 2026-10-26)
- Start date: 2016-02 (registry gives no type) (ClinicalTrials.gov record NCT02817360, source copy `cardio:ctgov-nct02817360-2023-03-14`, retrieved 2026-10-26)
- Primary completion: 2025-12 (anticipated) (ClinicalTrials.gov record NCT02817360, source copy `cardio:ctgov-nct02817360-2023-03-14`, retrieved 2026-10-26)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT02817360, source copy `cardio:ctgov-nct02817360-2023-03-14`, retrieved 2026-10-26)
- Countries: Austria; Netherlands; New Zealand; Spain; United Kingdom (ClinicalTrials.gov record NCT02817360, source copy `cardio:ctgov-nct02817360-2023-03-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02817360-2023-03-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients
- Condition: Heart Diseases
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): RAS-antagonist and beta-blocker up-to maximal dosages
- Intervention (Other): RAS-antagonist and beta-blocker none or at stable dose
- Lead sponsor: Martin Huelsmann
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 423f6df216a3a37bee65091406195a338b04f9d776847a86d55402e6deabb9e9
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
